A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2011
At a glance
- Drugs Docetaxel; SGN-15
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Oct 2011 Actual end date Dec 2005 added as reported by ClinicalTrials.gov.
- 24 Jul 2007 Status changed from suspended to completed.
- 06 Sep 2005 New trial record.